pSLQ5079_pHR_PGK_sfGFP_CoV-F1
(Plasmid
#155303)
-
PurposeSARS-CoV-2 fluorescent reporter 1
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 155303 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepHR
- Backbone size w/o insert (bp) 8965
- Total vector size (bp) 11682
-
Vector typeMammalian Expression, Lentiviral
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameSuperfolder GFP fused with SARS-CoV-F1
-
Alt nameSFGFP
-
Alt nameSARS-CoV-F1
-
SpeciesSynthetic
-
Insert Size (bp)2717
-
Entrez GeneORF1ab (a.k.a. GU280_gp01)
- Promoter PGK
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer CATTCTGCACGCTTCAAAAG
- 3′ sequencing primer CATAGCGTAAAAGGAGCAACA (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pSLQ5079_pHR_PGK_sfGFP_CoV-F1 was a gift from Stanley Qi (Addgene plasmid # 155303 ; http://n2t.net/addgene:155303 ; RRID:Addgene_155303) -
For your References section:
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, Pande T, Endy D, La Russa MF, Lewis DB, Qi LS. Cell. 2020 May 14;181(4):865-876.e12. doi: 10.1016/j.cell.2020.04.020. Epub 2020 Apr 29. 10.1016/j.cell.2020.04.020 PubMed 32353252